Scottish Medicines Consortium accepts Iluvien for chronic DME

The Scottish Medicines Consortium, after assessing and reviewing a simple patient access scheme, has accepted Iluvien for restricted use within the National Health Service Scotland, according to a press release from Alimera Sciences.

Patients in Scotland considered insufficiently responsive to available therapies for chronic diabetic macular edema will now have access to Iluvien (sustained-release fluocinolone acetonide), according to the release. 

The advice is restricted to those with a pseudophakic eye, and re-treatment with Iluvien is predicated on a positive response to and subsequent need for the product, the release said.